KIORA PHARMACEUTICALS INC (KPRX) 0.147 -0.01 (-5.16%)
0.147 -0.01 (-5.16%)
US49721T1016 - Common Stock - Premarket: 0.1489 +0 (+1.29%)
Fundamental Rating
Taking everything into account, KPRX scores 1 out of 10 in our fundamental rating. KPRX was compared to 264 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of KPRX have multiple concerns. KPRX has a expensive valuation and it also scores bad on growth
Profitability
Profitability Rating
KPRX has negative profitability rations, so we won't be analyzing them here.
KPRX's Return On Assets of -83.66% is worse than the rest of the industry. The industry average Return On Assets is -37.75%. 81% of the industry peers have a better Return On Assets.
The Piotroski-F score of KPRX is 2.00. This is a very weak score and indicates problems in health and profitability for KPRX.
VS Industry
ROA (-83.66%) VS Industry: 19% outperformed.
-838.18
81.41
Valuation
Valuation Rating
When comparing the current price to the book value of KPRX, it is valued rather cheaply. It is trading at 0.17 times its book value.
Compared to an average industry price book ratio of 1.90, KPRX is valued rather cheaply. On top of this, KPRX is cheaper than 100% of the companies listed in the same industry.
Compared to an average Enterprise Value to EBITDA ratio of 6.38, KPRX is valued rather cheaply. On top of this, KPRX has a better ratio than 82% of the companies listed in the same industry.
KPRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KPRX. No positive earnings are expected for the next year.
VS Industry
Price/Book (0.17) VS Industry: 100% outperformed.
117.15
0.17
Enterprise Value/ EBITDA (0.28) VS Industry: 82% outperformed.
886,335.20
0.01
Growth
Growth Rating
The Earnings Per Share has grown by an nice 19.25% over the past year.
Based on estimates for the next 5 years, KPRX will show a small growth in Earnings Per Share. The EPS will grow by 8.89% on average per year.
KPRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | 19.25% | 50.28% | 22.96% | 17.34% | 8.89% |
| Revenue | N/A | N/A | -100% | N/A | N/A | N/A | N/A |
Health
Health Rating
KPRX has a Current Ratio of 2.60. This indicates that KPRX is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 2.60 indicates that KPRX has no problem at all paying its short term obligations.
The Quick Ratio is in line with the industry averages, which is at 3.43.
The Debt to Equity ratio of KPRX is in line with the industry averages.
When comparing the Current Ratio of KPRX to the average industry Current Ratio of 3.93, KPRX is less able to pay its short term obligations than its industry peers.
KPRX has an Altman-Z score of -12.22. This is a bad value and indicates that KPRX is not financially healthy and even has some risk of bankruptcy.
Compared to an average industry Altman-Z score of 0.01, KPRX is in worse financial state than most of its industry peers. 92% of its industry peers have a better Altman-Z score.
KPRX has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for KPRX.
VS Industry
Debt/Equity (0) VS Industry: 55% outperformed.
15.82
0.00
Quick Ratio (2.6) VS Industry: 43% outperformed.
0.08
201.08
Current Ratio (2.6) VS Industry: 36% outperformed.
0.11
201.08
Altman-Z (-12.22) VS Industry: 8% outperformed.
-264.33
625.01
Dividend
Dividend Rating
KPRX does not give a dividend.
KIORA PHARMACEUTICALS INC0.147
NASDAQ:KPRX (8/16/2022, 7:00:03 PM)-0.01 (-5.16%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Pharmaceuticals | ||
| Earnings (Last) | 08-12 2022-08-12/bmo | Earnings (Next) | 11-14 2022-11-14 |
| Ins Owners | 0.97% | Inst Owners | 64.16% |
| Market Cap | 1.92M | Analysts | 82.5 |
| PE | N/A | Fwd PE | N/A |
| PEG (NY) | N/A | PEG (5Y) | N/A |
| P/S | N/A | P/B | 0.17 |
| EV/EBITDA | 0.28 | ||
| ROA | -83.66% | ROE | N/A |
| PM | N/A | Asset Turnover | N/A |
| EPS 1Y | 19.25% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | 27.03% |
| EPS Next Y | 50.28% | EPS Next 2Y | 22.96% |
| EPS Next 3Y | 17.34% | EPS Next 5Y | 8.89% |
| Revenue growth 1Y | -100% | Revenue growth 3Y | N/A |
| Revenue growth 5Y | N/A | Revenue growth Q2Q | N/A |
| Revenue Next Year | N/A | Revenue Next 2Y | N/A |
| Revenue Next 3Y | N/A | Revenue Next 5Y | N/A |
| Current Ratio | 2.6 | Quick Ratio | 2.6 |
| Altman-Z | -12.22 | F-Score | 2 |
| Debt/Equity | 0 | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA